A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica.
Jonathan GiovannelliJonathan CironMikael CohenHo-Jin KimSu-Hyun KimJan-Patrik StellmannIngo KleiterMorgan McCrearyBenjamin M GreenbergRomain DeschampsBertrand AudoinElisabeth MaillartCaroline PapeixNicolas CollonguesBertrand BourreDavid LaplaudXavier AyrignacFrançoise Durand-DubiefAurélie RuetSandra VukusicRomain MarignierLuc DauchetHelene Zephirnull nullPublished in: Annals of clinical and translational neurology (2021)
The findings suggest that RTX is more efficient than MMF as a first-line therapy. Even if the results of our meta-analysis cannot conclude that RTX has a better efficacy in delaying the first relapse than AZA, the observed effect difference between both treatments combined with the results of previous studies using as outcome the annualized relapse rate may be in favor of RTX.